Shanghai Alebund

Alebund Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for patients with chronic kidney disease (CKD) and related metabolic disorders. Founded in 2018 and headquartered in Shanghai, the company has built a comprehensive pipeline targeting renal diseases, including hyperphosphatemia, secondary hyperparathyroidism, and hyperkalemia. Its lead programs include tenapanor (AP-301), a first-in-class NHE3 inhibitor licensed from Ardelyx, and evocalcet (AP-302), a calcimimetic licensed from Chugai Pharmaceutical. Alebund combines strategic in-licensing of late-stage assets with internal R&D efforts to address significant unmet medical needs in the nephrology space. The company is backed by prominent life science investors, including Lilly Asia Ventures and Quan Capital.